v3.25.2
Related Party - Gilead Sciences, Inc. (Details)
$ / shares in Units, shares in Millions, $ in Millions
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2025
USD ($)
$ / shares
Mar. 31, 2025
USD ($)
shares
Jun. 30, 2024
USD ($)
Mar. 31, 2024
USD ($)
shares
Jun. 30, 2025
USD ($)
member
$ / shares
Jun. 30, 2024
USD ($)
Dec. 31, 2023
USD ($)
program
Dec. 31, 2021
USD ($)
program
Dec. 31, 2020
USD ($)
Dec. 31, 2024
USD ($)
Related Party Transaction [Line Items]                    
Sale of stock, consideration received on transaction   $ 150.0                
Number of programs, eligible to receive regulatory and commercial milestone payments | program             4      
Revenue recognized from amounts in deferred revenue at the beginning of the period $ 160.0   $ 39.0   $ 188.0 $ 180.0        
Accounts payable 29.0       29.0         $ 18.0
Receivable from collaboration partners, current $ 15.0       $ 15.0         20.0
Gilead                    
Related Party Transaction [Line Items]                    
Sale of stock, consideration received on transaction   $ 15.0                
Gilead                    
Related Party Transaction [Line Items]                    
Sale of stock, number of shares acquired in transaction (in shares) | shares   1.4                
Related Party                    
Related Party Transaction [Line Items]                    
Percentage of outstanding common stock held 29.50%       29.50%          
Accounts payable $ 13.0       $ 13.0         0.0
Receivable from collaboration partners, current 4.0       4.0         $ 6.0
Related Party | Research and Development                    
Related Party Transaction [Line Items]                    
Reimbursement from related party for shared costs $ 13.0   (14.0)   $ 8.0 (30.0)        
Purchase Agreement | Related Party                    
Related Party Transaction [Line Items]                    
Common stock shares issued (in shares) | shares       15.2            
Funds received for stock purchase agreement       $ 320.0            
Purchase price of common stock allocation to performance obligation       $ 87.0            
Percentage of premium purchase price of common stock         20.00%          
Trailing days average closing price         5 days          
Weighted average closing price of our common stock on grant date (in dollars per share) | $ / shares $ 33.54       $ 33.54          
Number of board members | member         3          
Purchase Agreement | Related Party | Maximum                    
Related Party Transaction [Line Items]                    
Right to purchase additional outstanding voting common stock percentage 35.00%       35.00%          
Gilead Collaboration Agreement                    
Related Party Transaction [Line Items]                    
Option payment upon completion of certain IND-enabling activities               $ 60.0    
Option payment upon achievement of certain development milestones               150.0    
Gilead Collaboration Agreement | Related Party                    
Related Party Transaction [Line Items]                    
Collaboration term for current and future clinical programs                 10 years  
Option continuation payment due upon eighth anniversary of agreement   $ 100.0                
Option continuation payment due upon second anniversary of agreement   100.0                
Option continuation payment due upon fourth anniversary of agreement   100.0                
Option continuation payment due upon sixth anniversary of agreement   $ 100.0                
Upfront cash payment                 $ 175.0  
Option fee per program for all other programs entering clinical development to exercise option               $ 150.0    
Number of research programs | program               2    
Revenue recognized from amounts in deferred revenue at the beginning of the period $ 160.0   $ 36.0   $ 188.0 $ 177.0        
Gilead Collaboration Agreement | Related Party | Maximum                    
Related Party Transaction [Line Items]                    
Potential regulatory approval milestones payment receivable related to domvanalimab               $ 500.0    
Amended Gilead Collaboration Agreement                    
Related Party Transaction [Line Items]                    
Number of exercise option to programs | program               3    
Option payments received               $ 725.0    
Removal of option continuation payment under agreement               $ 100.0    
Option payment upon achievement of certain development milestones             $ 150.0      
Number of programs, eligible to receive regulatory and commercial milestone payments | program             2      
Amended Gilead Collaboration Agreement | Related Party                    
Related Party Transaction [Line Items]                    
Upfront cash payment             $ 17.5      
Number of research programs | program             2      
Option payment upon completion of certain IND-enabling activities             $ 45.0      
Total upfront cash payment             35.0      
Amended Gilead Collaboration Agreement | Related Party | Maximum                    
Related Party Transaction [Line Items]                    
Regulatory and commercial milestone payments received             $ 375.0